`Filed: February 12, 2016
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`COALITION FOR AFFORDABLE DRUGS VI LLC
`Petitioner,
`
`v.
`
`CELGENE CORPORATION
`Patent Owner
`
`
`
`________________
`
`Case IPR2015-01103
`Patent 6,315,720
`________________
`
`MOTION TO SEAL
`
`
`
`
`
`Motion to Seal
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01103
` Patent 6,315,720
`
`Pursuant to 37 C.F.R. § 42.14, Patent Owner Celgene Corporation
`
`(“Celgene”) respectfully requests that the Patent Trial and Appeal Board (the
`
`“Board”) seal the unredacted versions of the Patent Owner Response, Ex. 2059
`
`(“Frau Declaration”), and Ex. 2060 (“DiPiro Declaration”), which discuss
`
`confidential Exhibit 2007.1 Pursuant to Appendix B to the Trial Practice Guide,
`
`Celgene is concurrently filing non-confidential versions of the Patent Owner
`
`Response, Frau Declaration, and DiPiro Declaration, with the confidential material
`
`reacted.
`
`Exhibit 2007, and the portions of the Patent Owner Response, Frau
`
`Declaration, and DiPiro Declaration discussing Exhibit 2007, contain Celgene’s
`
`business confidential information. Specifically, Exhibit 2007 is a confidential,
`
`non-public submission to the U.S. Food and Drug Administration that is part of
`
`Celgene’s New Drug Application for Thalomid®. Exhibit 2007 has not been
`
`previously disclosed to the public and remains confidential. See 21 C.F.R. §
`
`314.81. Good cause therefore exists for sealing these documents.
`
`For the foregoing reasons, Celgene respectfully requests that the Board enter
`
`an Order sealing the unredacted versions of the Patent Owner Response, Frau
`
`Declaration, and DiPiro Declaration.
`
`
`
`
`1 Celgene previously moved to seal Ex. 2007 on July 28, 2015. See Paper 9.
`
`
`
`
`
`Motion to Seal
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01103
` Patent 6,315,720
`
`Date: February 12, 2016
`
` Respectfully submitted,
`
`By: /F. Dominic Cerrito (Reg. No. 38,100)/
` F. Dominic Cerrito (Reg. No. 38,100)
` Andrew S. Chalson (pro hac vice)
` Eric C. Stops (Reg. No. 51,163)
` Frank C. Calvosa (Reg. No. 69,064)
` QUINN EMANUEL URQUHART &
` SULLIVAN, LLP
` 51 Madison Avenue, 22nd Floor
` New York, NY 10010
` Tel: (212) 849-7000
` Fax: (212) 849-7100
` nickcerrito@quinnemanuel.com
` ericstops@quinnemanuel.com
` andrewchalson@quinnemanuel.com
` frankcalvosa@quinnemanuel.com
`
`Anthony M. Insogna (Reg. No. 35,203)
`J. Patrick Elsevier (Reg. No. 44,668)
`JONES DAY
`12265 El Camino Real
`Suite 200
`San Diego, CA 92130
`Tel: (858) 314-1200
`Fax: (858) 314-1150
`aminsogna@jonesday.com
`jpelsevier@jonesday.com
`
`Gasper J. LaRosa
`JONES DAY
`222 E 41st Street
`New York, NY 10017
`Tel: (212) 326-3939
`Fax: (212) 755-7306
`gjlarosa@jonesday.com
`
`Attorneys for Celgene Corporation
`
`
`
`- 2 -
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`COALITION FOR AFFORDABLE DRUGS VI LLC
`Petitioner,
`
`v.
`
`CELGENE CORPORATION
`Patent Owner
`
`________________
`
`Case IPR2015-01103
`Patent 6,315,720
`________________
`
`
`CERTIFICATE OF SERVICE
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certifies that Patent
`
`Owner’s MOTION TO SEAL was served on February 12, 2016 by filing this
`
`document through the Patent Review Processing System, as well as e-mailing a
`
`copy to sarah.spires@skiermontderby.com, parvathi.kota@skiermontderby.com,
`
`and paul.skiermont@skiermontderby.com.
`
`Date: February 12, 2016
`
` Respectfully submitted,
`
`By: /F. Dominic Cerrito (Reg. No. 38,100)/
` F. Dominic Cerrito (Reg. No. 38,100)
` QUINN EMANUEL URQUHART &
` SULLIVAN, LLP
` 51 Madison Avenue, 22nd Floor
` New York, NY 10010
` General Tel: (212) 849-7000
` Fax: (212) 849-7100
` nickcerrito@quinnemanuel.com
`
`Lead Counsel for Celgene Corporation